Orlaam(LAAM) Alert


T01-15 Print Media:
301-827-6242
April 20, 2001 Broadcast Media:
301-827-3434
  Consumer Inquiries:
888-INFO-FDA
The U.S. Food and Drug Administration
(FDA) issued a new warning about
health risks associated with levomethadyl
acetate HC, a.k.a. Orlaam, a drug
used to treat opiate addiction.

FDA Announces Labeling
Changes Following Cardiac Adverse Events With Addiction Drug

The FDA is strengthening warnings to physicians
about serious cardiac adverse events associated with Orlaam (levomethadyl
acetate HC), a drug for opiate addiction treatment.

FDA has changed the Orlaam labeling to increase
the strength of the warnings and to highlight these warnings in a black
box, the most prominent warning on prescription drugs.

In addition, the approved indication for Orlaam
will be revised to indicate that the drug is not to be used as first line
therapy. Orlaam should be reserved for use in treatment of opiate-addicted
patients who fail to show an acceptable response to other adequate
treatments for addiction.

As of March 30, 2001, 10 cases of serious
arrhythmias have been submitted to FDA through MedWatch — FDAs safety
surveillance program. An estimated 33,000 patients have been treated with
Orlaam to date.

Roxane Laboratories, Inc., the drugs
manufacturer, mailed a Dear Healthcare Professional letter on April 18 to
physicians licensed to treat narcotic addiction.

Approved in 1993, Orlaam can be given less often
than methadone, which means that patients visit the clinic less frequently
and do not need to bring medication home.

At the time of approval there was a signal that
the drug may prolong cardiac conduction, and as a result, the labeling
included precautions about cardiac adverse events. Since the drugs
approval, FDA has received small but increasing numbers of adverse event
reports. In addition, European regulatory agencies have also received
reports of serious cardiac arrythmias, or deviations of the normal heart
rhythm.

ORLAAM is contraindicated in patients with known
or suspected arrythmias and any drug known to have the potential to cause
abnormal heart rhythm should not be used together with Orlaam.

If a patient taking Orlaam experiences
palpitations, dizziness, light-headedness, or seizures, the patient should
seek medical attention.

More information about ORLAAM and labeling
changes, is available from Roxane Laboratories Technical Product
Information at 1-800-962-8364. Cases of adverse events may be reported to
1-800-FDA-0178, or on the internet at www.fda.gov/medwatch.

 


On Thursday, April 19, 2001, a statement
was released by The European Agency
for the Evaluation of Medicinal Products –
EMEA – which is to be found at
the following “address”:
http://www.emea.eu.int/   
Click on the “Product Alert” button.
This alert it advises MDs “to review
their patients [receiving LAAM]
immediately.
In addition, physicians are advised to switch their patients
from
Orlaam to another existing alternative, e.g., methadone.”
The recommendations involve
“suspending the marketing authorizations of
Orlaam.”
Anyone taking LAAM needs to be reevaluated
immediately!   If there is any way possible, have your treatment
provider change your medication to methadone until more is known about the
risks involved with using LAAM.

Similar Posts

  • Office Based Opioid Treatment

    Admin 04/17/2023

    Treatment INDEX   OBOT PUBLICATIONS- Federal Code, Manuals, Teaching Packets, and other OBOT information.   BASIC INFORMATION FOR PHYSICIANS   NAMA’s Comments to the Federation of State Medical Boards   Physicians’ Guide: Opioid Agonist Medical Maintenance Treatment   Using Buprenorphine for Office Based Opioid Treatment (pdf file)   Manual For Methadone Medical Management (pdf file)

  • Methadone Authorities

    Admin 01/15/2022

    Alabama Website: http://www.mh.state.al.us/services/sa/sa-main.html Click Here for Website Contact Person: Kathy E. Sawyer Commissioner Email: [email protected] Substance Abuse Services Division AL DMHMR RSA Union Building Montgomery, AL 36130 Phone: (334) 242-3107 Fax: (334) 242-0727 DMHMR Email: [email protected] Toll Free Alabama Number: (800) 367-0955 Alaska Website: http://www.hss.state.ak.us/dbh/default.htm Click Here for Website Robert Hammaker Interim Treatment and Recovery…

  • Late Breaking News

    Admin 10/18/2022

    New Methadone Regulations The comment period is now over. CSAT has formed a committee to review the comments and the regulations. A short meeting is planned for January 31, 2000. Two NAMA officers are on the committee Lisa Torres, Esq. and Joycelyn Woods. Buprenorphrine Committee A federal committee has been formed to review the guidelines…

  • Resources

    Admin 02/26/2022

    COVID-19 Resources Get Federal, State, Organization and other information. more info Find Treatment Search our national database of treatment an other related resources. more info NAMA Library Get Federal, State, Organization and other information. more info We offer information about your rights under HIPPA and answers to frequently asked questions about the HIPPA rules. HIPPA…

  • Tag: ADA

    Admin 12/09/2022

    DOJ publishes guidance on Opioid Use Disorder and the Americans with Disabilities Act April 15, 2022 “The opioid crisis poses an extraordinary challenge to communities throughout our country. The Department of Justice (the Department) has responded with a comprehensive approach prioritizing prevention, enforcement, and treatment. This includes enforcing the Americans with Disabilities Act (Ada), which…

  • Nominations Open for the 2022 Richard Lane/Robert Holden Advocacy Award!

    Admin 03/06/2023

    Nominations Open for the 2022 Richard Lane/Robert Holden Advocacy Award! NAMA Recovery    AATOD Lane Holden Award    May 1, 2022  |  0 Richard Lane was a long-term heroin user who, upon release from prison in 1967, was instrumental in establishing one of the Nation’s first opioid treatment programs. In 1974, he became the Executive…